

Status: Currently Official on 17-Feb-2025  
Official Date: Official Prior to 2013  
Document Type: USP Monographs  
DocId: GUID-F88C3838-A620-406E-BE1D-153B9FB9EC3D\_1\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M900\\_01\\_01](https://doi.org/10.31003/USPNF_M900_01_01)  
DOI Ref: o0pb7

© 2025 USPC  
Do not distribute

# Acyclovir Tablets

## DEFINITION

Acyclovir Tablets contain NLT 90.0% and NMT 110.0% of the labeled amount of acyclovir ( $C_8H_{11}N_5O_3$ ).

## IDENTIFICATION

- A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

## ASSAY

### PROCEDURE

**Mobile phase:** 0.02 M acetic acid

**System suitability solution A:** 0.1 mg/mL each of [USP Acyclovir RS](#) and guanine. Dissolve in 0.1 N sodium hydroxide, and dilute with water.

**System suitability solution B:** 2.0 µg/mL of guanine. Dissolve in 0.1 N sodium hydroxide, and dilute with water.

**Standard solution:** 0.1 mg/mL of [USP Acyclovir RS](#). Dissolve in 0.1 N sodium hydroxide, and dilute with water.

**Sample solution:** Nominally 0.1 mg/mL of acyclovir prepared as follows. Transfer an amount of finely powdered Tablets equivalent to 10 mg of acyclovir (NLT 10 Tablets) to a 100-mL volumetric flask. Dissolve in 10 mL of 0.1 N sodium hydroxide, dilute with water to volume, and filter.

### Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC

**Detector:** UV 254 nm

**Column:** 4.6-mm × 25-cm; packing L1

**Column temperature:** 40°

**Flow rate:** 1.5 mL/min

**Injection volume:** 20 µL

### System suitability

**Samples:** *System suitability solution A* and *System suitability solution B*

[NOTE—The relative retention times for guanine and acyclovir are about 0.6 and 1.0, respectively, in *System suitability solution A*.]

### Suitability requirements

**Resolution:** NLT 2.0 between guanine and acyclovir, *System suitability solution A*

**Relative standard deviation:** NMT 2.0% for the acyclovir peak, *System suitability solution A*; NMT 2.0%, *System suitability solution B*

### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of acyclovir ( $C_8H_{11}N_5O_3$ ) in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response from the *Sample solution*

$r_S$  = peak response from the *Standard solution*

$C_S$  = concentration of [USP Acyclovir RS](#) in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of acyclovir in the *Sample solution* (mg/mL)

**Acceptance criteria:** 90.0%–110.0%

## PERFORMANCE TESTS

### DISSOLUTION (711)

**Medium:** 0.1 N hydrochloric acid; 900 mL

**Apparatus 2:** 50 rpm

**Time:** 45 min

### Instrumental conditions

**Mode:** UV

**Wavelength:** 254 nm

**Standard solution:** [USP Acyclovir RS](#) in *Medium*

**Sample solutions:** Dilute with *Medium* to a concentration that is similar to the *Standard solution*.

**Analysis:** Determine the amount of acyclovir ( $C_8H_{11}N_5O_3$ ) dissolved from UV absorption at the wavelength of maximum absorbance on filtered portions of the solution under test.

**Tolerances:** NLT 80% (Q) of the labeled amount of acyclovir ( $C_8H_{11}N_5O_3$ ) is dissolved.

- [UNIFORMITY OF DOSAGE UNITS \(905\)](#): Meet the requirements for *Weight Variation*

## IMPURITIES

### • PROCEDURE

**Mobile phase, System suitability solution A, System suitability solution B, Sample solution, Chromatographic system, and System suitability:** Proceed as directed in the Assay.

### Analysis

**Sample:** *Sample solution*

Calculate the percentage of each impurity in the portion of Tablets taken:

$$\text{Result} = (r_U / r_T) \times 100$$

$r_U$  = peak response for each impurity

$r_T$  = sum of the responses for all of the peaks

### Acceptance criteria

**Guanine:** NMT 2.0%

**Any other impurity:** NMT 0.5%

## ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers. Store between 15° and 25°. Protect from light and moisture.
- [USP REFERENCE STANDARDS \(11\)](#),  
[USP Acyclovir RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
ACYCLOVIR TABLETS	<a href="#">Documentary Standards Support</a>	SM12020 Small Molecules 1
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM12020 Small Molecules 1

**Chromatographic Database Information:** [Chromatographic Database](#)

### Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 30(2)

**Current DocID:** [GUID-F88C3838-A620-406E-BE1D-153B9FB9EC3D\\_1\\_en-US](#)

**DOI:** [https://doi.org/10.31003/USPNE\\_M900\\_01\\_01](https://doi.org/10.31003/USPNE_M900_01_01)

**DOI ref:** [o0pb7](#)